Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
NEW ORLEANS, Oct. 13, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 23, 2017 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE:TEVA), if they purchased the Company’s American Depository Shares (“ADSs”) and/or shares on the Tel Aviv Stock Exchange between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
What You May Do
If you purchased ADSs or shares of Teva Pharmaceutical and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-teva/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by October 23, 2017.
About the Lawsuit
Teva Pharmaceutical and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 3, 2017, Teva disclosed the recording of a goodwill impairment charge of $6.1 billion for Q2 2017 related to the acquisition of Actavis Generics as a result of poor performance in its U.S. generics sector, as well as lower overall expected poor performance due to increased competition and delays in product launches.
On this news, the price of Teva Pharmaceutical’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
